ArticleJournal of immunology (Baltimore, Md. : 1950)2000
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Article in Journal of immunology (Baltimore, Md. : 1950), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 125 citations in OpenAlex.
- Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.Journal of immunotherapy (Hagerstown, Md. : 1997)Trial
- Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.Pharmaceutics · 2022Review
- Article
- Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.Journal for immunotherapy of cancer · 2020Article
- High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.International journal of molecular sciences · 2018Review
- Immune targets and neoantigens for cancer immunotherapy and precision medicine.Cell research · 2017Review
- Article
- Harnessing the Microbiome to Enhance Cancer Immunotherapy.Journal of immunology research · 2015Review
- An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.PloS one · 2015Article
- Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Advances in immunology · 2012Review
- Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes.Results in immunology · 2012Article
- GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.The Journal of investigative dermatology · 2012Article
- Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.The Journal of clinical investigation · 2010Article
- GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2009Article
- Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.Journal of oncology · 2009Article
- MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Toll-like receptors in tumor immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
CD4+ T cells play a central role in the induction and persistence of CD8+ T cells in several models of autoimmune and infectious disease. To improve the efficacy of a synthetic peptide vaccine based on the self-Ag, gp100, we sought to provide Ag-specific T cell help. To identify a gp100 epitope restricted by the MHC class II allele with the highest prevalence in patients with malignant melanoma (HLA-DRB1*0401), we immunized mice transgenic for a chimeric human-mouse class II molecule (DR4-IE) with recombinant human gp100 protein. We then searched for the induction of CD4+ T cell reactivity using candidate epitopes predicted to bind to DRB1*0401 by a computer-assisted algorithm. Of the 21 peptides forecasted to bind most avidly, murine CD4+ T cells recognized the epitope (human gp10044-59, WNRQLYPEWTEAQRLD) that was predicted to bind best. Interestingly, the mouse helper T cells also recognized human melanoma cells expressing DRB1*0401. To evaluate whether human CD4+ T cells could be generated from the peripheral blood of patients with melanoma, we used the synthetic peptide h-gp10044-59 to sensitize lymphocytes ex vivo. Resultant human CD4+ T cells specifically recognized melanoma, as measured by tumor cytolysis and the specific release of cytokines and chemokines. HLA class II transgenic mice may be useful in the identification of helper epitopes derived from Ags of potentially great clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.